Clinical Trial Update: Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE [Phase 2]

View source ↗

Summary

This is a Phase 2 extension study to assess the safety and tolerability of NBI-921352 as an adjunctive therapy for patients with SCN8A developmental epileptic e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scn8a Developmental Epileptic Encephalopathy

Drugs mentioned

• NBI-921352 (NBI-921352)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING